PLX 4720

Known as: PLX-4720, PLX4720 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Intravital imaging of BRAF-mutant melanoma cells containing an ERK/MAPK biosensor reveals how the tumor microenvironment affects… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
During progression of melanoma, malignant melanocytes can be reprogrammed into mesenchymal-like cells through a process similar… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Malignant astrocytomas (MA) are aggressive central nervous system tumors with poor prognosis. Activating mutation of BRAF… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Although B-Raf(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BRAF(V600E) is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting "active" protein… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Human respiratory viruses are a diverse group of pathogens composed of hundreds of virus strains, and this presents a major… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?